104sek
-1,3 %
Date:2025-05-14Time:17:24:55Latest report:Q4-2024List:First NorthTicker:KAN
Market Cap:126 msekEnterprise Value:79 msekNet Sales:- msekEarnings:-44,6 msekEmployees:0ISIN:SE0015658570

Ratios

10-year key figure history for Kancera turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Kancera with index and moving average MA50 and MA200.

Stockprice:1,04
MA50:1,18
MA200:1,45
Price/MA200:-28,4 %
RSI (14):40,1
Price/MA50:-12,0 %

Description

Kancera is a pharmaceutical company. The company develops pharmaceuticals that counteract injuries in acute and chronic inflammation. The products are developed primarily to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe virus infections. Kancera is planning two Phase II clinical trials, in covid-19 and in cardiac patients. Kancera conducts research and development within Karolinska Institutet Science Park in Stockholm.

Biotechnology